Ciltacabtagene Autoleucel: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and DMC (Denmark), among others, recommended or restricted ciltacabtagene autoleucel, while NYE METODER (Norway) did not recommend it.
The record spans 4.2 years, opening at AWMSG (Wales) on 7 Apr 2022 and running to 24 Jun 2026.
ZIN (Netherlands) changed its position: not recommended on 20 Oct 2022, restricted by 27 May 2026, after a resubmission.
No assessment is on file from PBAC (Australia), SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for ciltacabtagene autoleucel, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 14 of 17 records date from 2023 or later.
AWMSG (Wales) was first to assess ciltacabtagene autoleucel, on 7 Apr 2022; DMC (Denmark) did not open a file until 24 Jun 2026 — a wide spread of 4.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
5 of the 10 agencies here assessed ciltacabtagene autoleucel more than once, ZIN (Netherlands) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for ciltacabtagene autoleucel.
The full ledger for ciltacabtagene autoleucel reads 8 recommended, 5 not recommended, 2 restricted and 1 terminated, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 24 Jun 2026 | Knoglemarvskræft | Anbefalet | source |
| NYE METODER (Norway) | 14 Jun 2026 | Behandling av voksne pasienter med residiverende og refraktær myelomatose, som har fått minst én tidligere behandling, i… | not introduced | source |
| ZIN (Netherlands) | 27 May 2026 | Advies - alleen vergoeden na prijsdaling ciltacabtagene autoleucel (Carvykti®) voor de behandeling van multipel myeloom … | reimburse only after price negotiation (sluis) | source |
| AIFA (Italy) | 4 Apr 2026 | CARVYKTI è indicato per il trattamento di pazienti adulti con mieloma multiplo recidivato e refrattario che hanno ricevu… | innovative · reimbursed class H | source |
| AOTMIT (Poland) | 29 Dec 2025 | programu lekowego B.54. „Leczenie chorych na szpiczaka plazmocytowego (ICD-10: C90.0) | recommended conditionally | source |
12 further decisions for ciltacabtagene autoleucel, across 8 agencies, are not shown here. They include the most recent record on file, 24 Jun 2026 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 17 decisions for ciltacabtagene autoleucel from 10 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.